S&P 500 Healthcare Sector SEC Filings — June 05, 2026

05-06-2026

Lucid Group held its 2026 Annual Meeting on June 4, 2026, where stockholders approved all four proposals, including the election of nine directors, ratification of KPMG as auditor, advisory approval of executive compensation, and the amendment and restatement of the 2021 Stock Incentive Plan. The Plan increases the number of shares available for issuance by 23,500,000 shares. All director nominees received strong support, with votes for ranging from ~255.2M to ~260.4M, while the advisory vote on executive compensation saw ~255.95M for and ~5.41M against, indicating broad but not unanimous approval.

• · The record date for the Annual Meeting was April 6, 2026.
• · Ratification of KPMG as independent auditor received 300,971,935 votes for, 1,906,185 against, and 1,157,127 abstentions.
• · Advisory vote on executive compensation: 255,952,612 for, 5,411,173 against, 251,876 abstentions.
• · Approval of the Stock Incentive Plan amendment: 253,997,107 for, 7,435,259 against, 183,295 abstentions.
• · Broker non-votes were 42,419,586 for all director elections and proposals except the auditor ratification (which had no broker non-votes).

05-06-2026

News Corp filed an 8-K on June 5, 2026, disclosing that it has provided daily transaction disclosures to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, which authorizes up to $1 billion in aggregate share repurchases of Class A and Class B common stock. The filing includes forward-looking statements about the company's intent to continue repurchasing shares from time to time, subject to market conditions and other factors.

• · The repurchase program authorizes up to $1 billion in aggregate of Class A and Class B common stock.
• · Disclosures to the ASX are required on a daily basis under ASX rules for any transactions under the program.
• · The filing includes forward-looking statements regarding the company's intent to repurchase shares, subject to market price, general market conditions, securities laws, and alternative investment opportunities.

05-06-2026

SPECIFICITY, INC. filed a 10-K/A restating its FY2025 financials, with net loss widening 17.1% to $554,067 (from $473,147 as previously reported) due to a 5.1% increase in cost of services and a 9.1% rise in other expense. Total current liabilities were revised upward by $121,122 (10.6%) and total equity worsened by $120,919 (20.6%), while total revenues were only marginally adjusted (+0.2% to $1,090,450). The filing also details executive compensation, with CEO Jason Wood receiving only $11,628 in total compensation for 2025, and notes the resignation of COO Richard Berry effective December 31, 2025.

• · The restatement increased total current assets by $203 (3.7%) to $5,737.
• · Total assets were minimally adjusted (+$203) to $1,555,601.
• · Net cash used in operating activities worsened by $54,254 (60.4%) to $149,371.
• · Net cash provided by financing activities increased by $54,457 (61.8%) to $147,945.
• · CEO Jason Wood received $0 salary and bonus in both 2025 and 2024; his total compensation dropped from $88,240 in 2024 to $11,628 in 2025.
• · COO Richard Berry received $97,679 in total compensation for 2025, up from $14,235 in 2024.
• · William Anderson and Kevin Frisbie received $0 total compensation in 2025.
• · The company uses Black-Scholes to value convertible debt derivatives (Level 2) and warrants (Level 2).
• · Freestanding stock issued as inducement for convertible debt is recorded as a debt discount and amortized over the debt term.

05-06-2026

Guidewire Software reported total revenue of $372.5M for Q3 FY2026 (three months ended April 30, 2026), up 26.9% YoY from $293.5M, driven by strong subscription and support revenue growth of 34.6% to $244.7M. However, net income declined to $16.5M from $46.0M in the prior year quarter, impacted by a $18.9M other expense versus a $34.1M gain. For the nine months, net income was $107.9M compared to $17.9M, a significant improvement. The company also repurchased $392.4M of common stock during the nine months.

• · Operating income improved to $30.6M in Q3 FY2026 from $4.5M in Q3 FY2025.
• · Total operating expenses were $206.0M in Q3 FY2026, up 15.6% YoY.
• · Stock-based compensation was $45.2M in Q3 FY2026 and $135.0M for nine months.
• · The company had $677.2M in convertible senior notes outstanding as of April 30, 2026.
• · Net cash provided by operating activities was $105.8M for nine months FY2026, up from $56.0M.
• · The company repurchased 1,696,180 shares in Q3 FY2026 for $251.0M.
• · Goodwill increased to $421.1M from $394.0M due to acquisitions.
• · Deferred revenue decreased to $304.4M from $344.8M.

05-06-2026

KeyCorp filed an S-3 registration statement on June 5, 2026, registering the resale of up to 158,723,874 common shares by The Bank of Nova Scotia, which holds an aggregate 158,981,769 shares (14.73% of outstanding shares). The shares were issued in two tranches in 2024 at $17.17 per share, with total proceeds to KeyCorp of approximately $2.8 billion. The filing does not involve new issuance or proceeds to KeyCorp, and the selling shareholder may sell shares through various methods.

• · The two tranches of the equity investment closed on August 30, 2024 (first) and December 27, 2024 (second).
• · KeyCorp will not receive any proceeds from the resale of shares by the selling shareholder.
• · The selling shareholder has a periodic 'true-up' right to participate pro rata in any KeyCorp share repurchases.
• · The filing incorporates by reference KeyCorp's 2025 10-K, Q1 2025 10-Q, and multiple Form 8-K filings (Jan-Jun 2026).
• · The selling shareholder's address is 40 Temperance Street, Toronto, Ontario, M5H 0B4.

05-06-2026

BNY Mellon Strategic Municipals, Inc. (LEO) filed a DEFA14A (additional proxy material) with the SEC on June 5, 2026. The filing is a graphic image (image01.jpg) with no extractable financial data or substantive textual disclosure beyond the header information.

• · Filing type: DEFA14A (additional proxy materials)
• · Filing date: June 5, 2026
• · Former company name: Dreyfus Strategic Municipals, Inc. (changed October 30, 2018)
• · SEC file number: 811-05245
• · Fiscal year end: September 30

05-06-2026

On June 1, 2026, New Mountain Net Lease Trust sold an aggregate of 613,712 common shares for approximately $12.6 million in a private placement exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D. The offering included Class F, Class I, and Class E shares, with Class I shares comprising the vast majority of the issuance.

• · The shares were sold at the most recently determined net asset value per share.
• · The offering was part of the company's continuous private offering program.
• · Class I shares accounted for 98.9% of total shares sold (607,209 of 613,712).

05-06-2026

Caribou Biosciences, Inc. (CRBU) is urging stockholders to vote ahead of its June 17, 2026 Annual Meeting, noting that many shares remain unvoted. The Board recommends voting FOR all four proposals, including the election of three Class II directors, ratification of Deloitte & Touche LLP as auditor, an officer exculpation amendment, and an adjournment proposal. The filing does not contain any financial results or performance metrics, so no positive or negative trends can be assessed.

• · Annual Meeting scheduled for June 17, 2026.
• · Proposal 1: Election of Andrew Guggenhime, David Johnson, and Nancy Whiting as Class II directors.
• · Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
• · Proposal 3: Amendment to certificate of incorporation for officer exculpation under Delaware law.
• · Proposal 4: Adjournment proposal to allow further solicitation if needed.
• · Stockholders can vote via Internet, telephone, or by following instructions on the proxy card.
• · Assistance available from D.F. King & Co., Inc. at 1-866-207-2356.

05-06-2026

BNY Mellon Strategic Municipal Bond Fund, Inc. (DSM) filed a DEFA14A additional proxy soliciting material on June 5, 2026, urging shareholders to vote on a proposal. The filing includes a 'Stop, Look & Listen' graphic and references to the fund's proxy statement. No financial figures or period-over-period comparisons are provided in this filing.

• · The filing is a DEFA14A (additional proxy soliciting material) filed on June 5, 2026.
• · The fund was formerly known as Dreyfus Strategic Municipal Bond Fund, Inc. (name changed October 30, 2018).
• · The fund is incorporated in Maryland and has a fiscal year end of November 30.
• · The filing includes a 'Stop, Look & Listen' graphic urging shareholders to vote.

05-06-2026

Assembly Biosciences, Inc. held its Annual Meeting on June 4, 2026, where stockholders approved all five proposals, including the election of nine director nominees, the ratification of Ernst & Young LLP as independent auditor, and the approval of amendments to the 2018 Stock Incentive Plan and Employee Stock Purchase Plan. The amendments increase the share reserve for the 2018 Plan from 1,478,333 to 2,678,333 shares and for the ESPP from 225,000 to 515,000 shares. All director nominees received strong support with votes for ranging from 11,274,020 to 11,312,521, while the advisory vote on executive compensation passed with 11,293,061 votes for and only 5,401 against.

• · The ratification of Ernst & Young LLP as independent auditor received 12,382,746 votes for, 2,943 against, and 175 abstain, with no broker non-votes.
• · The advisory vote on executive compensation passed with 11,293,061 votes for, 5,401 against, and 18,379 abstain.
• · Amendment No. 3 to the 2018 Plan was approved with 11,290,805 votes for, 24,242 against, and 1,794 abstain.
• · ESPP Amendment No. 2 was approved with 11,305,253 votes for, 9,343 against, and 2,245 abstain.
• · All director nominees received over 11.27 million votes for, with the lowest being John G. McHutchison at 11,274,020 votes for.

05-06-2026

Unicycive Therapeutics, Inc. (UNCY) entered into Amendment No. 2 to its Sales Agreement with Guggenheim Securities, LLC on June 5, 2026, increasing the aggregate offering price of shares that may be sold in the at-the-market (ATM) offering from $100,000,000 to $150,000,000. Concurrently, the company filed a Shelf Registration Statement on Form S-3 to sell an additional $50,000,000 of common stock in the ATM offering. This amendment expands the company's potential equity capital raising capacity by $50,000,000, but also increases potential dilution for existing shareholders.

• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
• · The common stock is traded on the Nasdaq Capital Market under the symbol UNCY.
• · The original Sales Agreement was dated November 13, 2024, and was first amended on November 14, 2025.

05-06-2026

UnitedHealth Group held its 2026 Annual Meeting on June 1, 2026, with 768,066,717 shares represented. All nine director nominees were elected, with support ranging from 89.68% (Charles Baker) to 98.96% (Kristen Gil). The non-binding advisory vote on executive compensation passed with 82.74% support, and the ratification of Deloitte & Touche LLP as auditor was approved with 95.00% of votes. However, a shareholder proposal requiring an independent board chair was rejected, receiving only 20.24% support.

• · Charles Baker received the lowest support among directors at 89.68% (606,637,150 for, 69,792,687 against).
• · Kristen Gil received the highest support among directors at 98.96% (670,734,403 for, 7,012,293 against).
• · The non-binding advisory vote on executive compensation had 117,731,618 against votes (17.26% of votes cast).
• · The shareholder proposal for an independent board chair received only 137,347,215 for votes versus 537,634,392 against.
• · Broker non-votes totaled 89,736,263 shares across all director elections and the compensation vote.

05-06-2026

LCI Industries announced the retirement of CEO Jason Lippert after 32 years and the appointment of independent director Johnny Sirpilla as interim CEO. Additionally, Virginia Henkels was named Chair of the Board, succeeding Tracy Graham, who stepped down. The Board will conduct a comprehensive search for a permanent CEO, considering both internal and external candidates.

• · Jason Lippert will serve in an advisory capacity for one year to support the transition.
• · Johnny Sirpilla has been an LCI Industries Board member since 2019.
• · Virginia Henkels has been a Board member since 2017.
• · Tracy Graham stepped down after 10 years of service to dedicate time to his core business.
• · The Board expressed confidence in the existing management team to maintain operations during the transition.

05-06-2026

EWSB Bancorp, Inc. held its Annual Meeting of Stockholders on June 4, 2026, where shareholders elected directors Kay M. Dorow and Steven Haen each for three-year terms, with approximately 366,000 votes for and 20,000 withheld, plus 157,254 broker non-votes. The appointment of Plante Moran, PLLC as the independent registered public accounting firm for the year ending December 31, 2026 was ratified unanimously with 543,558 votes in favor, no against or abstain votes, and no broker non-votes.

• · The company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
• · No extended transition period for complying with new financial accounting standards was elected.
• · The meeting was held on June 4, 2026, and the 8-K was filed on June 5, 2026.
• · Directors were elected for three-year terms or until successors are qualified.
• · The auditor ratification received unanimous support with zero votes against or abstaining.

05-06-2026

First Western Financial Inc. held its Annual Meeting on June 3, 2026, where shareholders elected eleven directors, ratified Crowe LLP as the independent auditor for FY2026, and approved the advisory say-on-pay proposal. While all proposals passed, the say-on-pay vote showed significant opposition with 1,218,437 votes against (20.0% of votes cast), indicating notable shareholder dissent on executive compensation.

• · All director nominees received strong support, with votes for ranging from 5,629,770 (Thomas A. Gart) to 6,067,380 (Scott C. Mitchell).
• · Ratification of Crowe LLP as auditor passed overwhelmingly with 6,578,057 votes for and only 181,161 against.
• · The say-on-pay proposal had 4,865,971 votes for, 1,218,437 against, and 4,384 abstentions, representing a 20% dissent rate.
• · Broker non-votes totaled 670,427 for each director nominee, indicating a significant portion of shares were not voted on director elections.

05-06-2026

FrontView REIT, Inc. filed an amendment (8-K/A) to its original 8-K filing to disclose that on June 1, 2026, the Board approved an equity grant to newly elected director Timothy McHugh. Mr. McHugh received 5,311 LTIP Units in the company's operating partnership, vesting on the earlier of the first anniversary or the day before the next annual meeting, subject to continued service. The filing provides additional details on the compensatory arrangement for the director.

• · The equity grant was approved on June 1, 2026, with a grant date value substantially equivalent to annual equity grants received by continuing non-employee directors on May 27, 2026.
• · The LTIP Units were granted under the Company's 2024 Omnibus Equity and Incentive Plan and the Amended and Restated Agreement of Limited Partnership of FrontView Operating Partnership LP.
• · Vesting occurs on the earlier of the first anniversary of issuance or the day before the Company's first annual stockholders' meeting held at least 50 weeks following issuance, subject to continued service.

05-06-2026

Jade Biosciences, Inc. (JBIO) announced the postponement of its 2026 Annual Meeting of Stockholders from 9:00 a.m. to 2:30 p.m. Pacific Time on the same day, June 9, 2026, for administrative purposes. The meeting will still be held virtually via live webcast, and the record date remains April 17, 2026. Stockholders who have already submitted proxies do not need to submit new ones.

• · Original meeting time was 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time.
• · Stockholders must register by 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time on June 7, 2026.
• · Record date for the meeting remains April 17, 2026.
• · Proxies already submitted remain valid; stockholders may revoke proxies following instructions in the proxy statement.

05-06-2026

Columbia Financial, Inc. reported net income of $13.1M for Q1 2026, up 47.2% from $8.9M in Q1 2025, driven by a 20.0% increase in net interest income to $60.4M. However, total non-interest income declined 20.4% to $6.7M, primarily due to a $1.2M loss on equity securities vs. a $0.3M gain in the prior year. Total assets decreased slightly to $11.01B from $11.02B at year-end 2025.

• · Total deposits decreased by $72.1M to $8.37B from $8.44B at year-end 2025.
• · Borrowings increased by $60.0M to $1.24B from $1.18B at year-end 2025.
• · Allowance for credit losses increased to $68.8M from $67.2M at year-end 2025.
• · Non-interest expense increased 8.3% YoY to $47.5M, including $1.8M in merger-related expenses.
• · Earnings per share (diluted) was $0.13 for Q1 2026 vs. $0.09 for Q1 2025.
• · Total comprehensive income was $11.2M for Q1 2026 vs. $18.2M for Q1 2025, due to other comprehensive loss of $1.9M.
• · Cash and cash equivalents decreased by $63.9M to $276.9M from $340.8M at year-end 2025.
• · Net cash used in investing activities was $56.9M, primarily for purchases of debt securities available for sale.
• · Net cash used in financing activities was $10.1M, driven by a decrease in deposits.

05-06-2026

New Fortress Energy Inc. announced the resignation of Chief Accounting Officer Michael Lowe, effective July 1, 2026, and the appointment of Frederick Hundt as his successor. Mr. Lowe provided exemplary leadership during the company's complex restructuring, which is nearing completion. The transition appears orderly with the successor already serving as Global Controller since June 2025.

• · Michael Lowe has been with the company since 2019, first as SVP then as CAO.
• · Before joining NFE, Mr. Lowe was a Director in PwC's Capital Markets and Accounting Advisory Services practice (2008-2019).
• · Frederick Hundt previously served as Corporate Controller of GXO Logistics (April 2023 to June 2025) and held finance/accounting leadership roles at Mastercard (2015-2023), including Assistant Corporate Controller.
• · Mr. Hundt spent 11 years in PwC's audit practice, including time in the national office supporting SEC reporting and compliance.
• · Mr. Hundt joined NFE in June 2025 as Global Controller and has already been working to strengthen the accounting organization.

05-06-2026

DeEtte Gray, President of U.S. Operations at CACI International Inc, notified the company of her retirement effective June 30, 2026. She will remain as a Strategic Advisor through December 31, 2026 under a Transition and Separation Agreement that provides a prorated base salary of $763,497, reduced bonus participation, and a significantly reduced long-term equity grant, but no severance or change-in-control benefits. The transition is intended to support an orderly leadership handover.

• · Transition Period runs from July 1, 2026 to December 31, 2026.
• · Ms. Gray will not be eligible for additional long-term incentive awards in 2026.
• · The Transition Agreement does not provide severance or change-in-control benefits.
• · Incentive compensation during the Transition Period is subject to the company's clawback policy.
• · The agreement was approved by the company's Human Resources and Compensation Committee.

05-06-2026

My City Builders, Inc. (MYCB) filed its 10-Q for the quarter ended April 30, 2026, reporting no revenue for both the three- and nine-month periods. The company recorded a net loss of $23,265 for the quarter (vs. $62,267 in Q2 2025) and a net loss of $117,509 for the nine months (vs. $215,051 in the prior year). While the net loss narrowed significantly due to the absence of discontinued operations losses, the company continues to operate without revenue and has a negative stockholders' equity of $30,540 as of April 30, 2026, compared to positive equity of $4,469 at July 31, 2025.

• · The company acquired land valued at $350,000 during the period, financed through a promissory note to a related party.
• · Operating expenses for the nine months ended April 30, 2026 were $100,792, up from $96,793 in the prior year period.
• · Interest expense - related party was $16,717 for the nine months ended April 30, 2026, compared to $0 in the prior year.
• · Net cash used in operating activities improved to $56,111 for the nine months ended April 30, 2026, from $644,036 in the prior year.
• · The company had no revenue and no discontinued operations in the current period, whereas the prior year included significant losses from discontinued operations ($117,130 for nine months).
• · As of April 30, 2025, discontinued operations had total assets of $4,290,327 and total liabilities of $5,566,709.

05-06-2026

Edgewise Therapeutics, Inc. held its Annual Meeting on June 4, 2026, where three Class II directors were elected, the appointment of KPMG LLP as independent auditor was ratified, and executive compensation received advisory approval. All proposals passed with strong shareholder support; however, two director nominees faced notable opposition, with Jonathan Root, M.D. receiving 31.9 million withhold votes (35.0%) and Badreddin Edris, Ph.D. receiving 27.0 million withhold votes (29.7%).

• · Total shares outstanding and voted not disclosed in filing.
• · Number of broker non-votes not disclosed.
• · Director Laura Brege received 87.3 million For votes (95.8%), the highest support among nominees.
• · Ratification of KPMG received 99.6 million For votes with only 1,123 Against and 578,031 Abstain, indicating overwhelming approval.
• · Advisory vote on executive compensation passed with 87.1 million For votes, but 3.5 million (3.8%) voted Against.

05-06-2026

Nanoviricides, Inc. filed a universal shelf registration statement on Form S-3 with the SEC on June 5, 2026, to offer and sell up to $50,000,000 of common stock, preferred stock, debt securities, warrants, rights, or units from time to time. The company's common stock is listed on NYSE American under the symbol NNVC. As of June 4, 2026, the aggregate market value of outstanding common stock held by non-affiliates was approximately $35,500,000, based on 22,982,000 shares outstanding and a closing price of $1.59 on June 2, 2026.

• · The shelf registration allows for delayed or continuous offerings under Rule 415.
• · The company is classified as a non-accelerated filer and a smaller reporting company.
• · The filing date is June 5, 2026, and the prospectus is dated June 2026.
• · The par value of common and preferred stock is $0.00001 per share.
• · The company's principal executive offices are located at 1 Controls Drive, Shelton, Connecticut 06484.

05-06-2026

Humacyte, Inc. received a letter from Nasdaq on June 5, 2026, confirming it has regained compliance with the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Global Select Market. The company had previously been notified of non-compliance on May 4, 2026, after its common stock closed below $1.00 for 30 consecutive business days. Nasdaq considers the matter closed.

• · The compliance period to regain bid price compliance was until November 2, 2026.
• · The company's common stock trades under the symbol HUMA on The Nasdaq Global Select Market.
• · The redeemable warrants trade under the symbol HUMAW on The Nasdaq Stock Market LLC.

05-06-2026

Jupiter Neurosciences, Inc. appointed Alison Silva as Chief Operating Officer and President, increasing her base salary to $340,200 from $315,000, and granted her options for 600,000 shares. The company also awarded discretionary bonus options in lieu of cash to five executives totaling approximately 2,101,726 shares, and granted 100,000 options to each independent non-employee director. All option grants vest quarterly over three years starting September 2, 2026.

• · Amendment No. 3 to employment agreement with Alison Silva dated June 5, 2026.
• · All option grants vest quarterly over three years starting September 2, 2026.
• · Discretionary bonus options were granted in lieu of cash.
• · The company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

05-06-2026

Synchrony Financial issued and sold 500,000 depositary shares, each representing a 1/100th interest in a share of newly created 7.250% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C, raising capital through a public offering. The offering was underwritten by BofA Securities, Barclays Capital, and Morgan Stanley, and the Series C terms impose restrictions on dividends and share repurchases if preferred dividends are not paid. No prior-period financial data is provided in this filing, so no period-over-period comparisons are available.

• · The Certificate of Designations for Series C Preferred Stock was filed with the Delaware Secretary of State on June 4, 2026.
• · The underwriting agreement was entered into on June 2, 2026, with BofA Securities, Barclays Capital, and Morgan Stanley as representatives.
• · The offering was made under the Company's existing shelf registration statement on Form S-3 (File No. 333-288729).
• · The Series C Preferred Stock carries a 7.250% fixed rate reset, is non-cumulative, and perpetual.
• · Dividend and share repurchase restrictions apply if Series C dividends are not declared and paid for the immediately preceding dividend period.

05-06-2026

Caris Life Sciences, Inc. held its 2026 Annual Meeting on June 4, 2026, where shareholders voted to elect ten director nominees and ratified the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. All director nominees were elected, though several received significant 'withheld' votes, with Peter M. Castleman receiving the highest number of withheld votes at 62,191,585 (23.7% of votes cast). The ratification of Deloitte & Touche LLP passed overwhelmingly with 273,517,324 votes in favor.

• · The record date for the meeting was April 9, 2026.
• · Broker non-votes totaled 11,087,026 for each director nominee.
• · Director David Fredrickson received the highest votes for (228,579,061) among all nominees.
• · Director Dr. Jeffrey Vacirca received the fewest votes withheld (33,954,010).
• · The ratification of Deloitte & Touche LLP had only 60,882 votes against and 136,314 abstentions.

05-06-2026

Lifeway Foods, Inc. announced on June 5, 2026, that its Board of Directors authorized the redemption of all outstanding preferred share purchase rights under its Shareholder Rights Agreement (dated November 4, 2024, as amended). The rights will be redeemed at $0.001 per Right, terminating the Rights Agreement effective immediately. This action modifies the rights of security holders by eliminating the poison pill provision.

• · The Shareholder Rights Agreement was originally dated November 4, 2024, and amended on October 29, 2025.
• · The redemption and termination are effective as of June 5, 2026.
• · After redemption, holders of Rights will only be entitled to receive the redemption price of $0.001 per Right.

05-06-2026

New Mountain Finance Corp priced a private offering of $150M in senior notes across three tranches on June 5, 2026. The offering includes $40M of 7.28% Series 2026A Senior Fixed Rate Notes due 2028 (Tranche A), $35M of 7.76% Series 2026A Senior Fixed Rate Notes due 2031 (Tranche B), and $75M of Series 2026A Senior Floating Rate Notes due 2031 (Tranche C). Proceeds will be used for general corporate purposes, including investments and debt repayment.

• · The offering is expected to close on or around June 18, 2026, subject to customary closing conditions.
• · Each tranche of the Notes is expected to be issued on or before October 1, 2026.
• · The Notes are being offered in reliance on Section 4(a)(2) of the Securities Act and will not be registered under the Securities Act or any state securities laws.
• · The company is not an emerging growth company as defined in Rule 405 of the Securities Act.

05-06-2026

MBX Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders elected Patrick J. Heron and Edward T. Mathers as Class II directors for three-year terms and ratified Ernst & Young LLP as independent auditor for fiscal 2026. The meeting had 47,570,485 shares outstanding as of the record date.

• · Patrick J. Heron received 35,007,623 votes for, 4,579,129 withheld, and 4,130,833 broker non-votes.
• · Edward T. Mathers received 31,983,223 votes for, 7,603,529 withheld, and 4,130,833 broker non-votes.
• · Ratification of Ernst & Young LLP received 43,713,693 votes for, 1,946 against, and 1,946 abstentions.

05-06-2026

Commercial Vehicle Group, Inc. (CVGI) filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration statement on June 4, 2026, solely to correct Exhibit 23.1 (Consent of Independent Registered Public Accounting Firm) that was filed in error with the original S-3 filed the same day. The company is registering the sale of up to $25,000,000 of securities comprising common stock, warrants, subscription rights, and units, to be offered from time to time on a delayed or continuous basis.

• · The filing is a corrective amendment (Amendment No. 1) to replace an incorrect Exhibit 23.1 from the original S-3 filed on June 4, 2026.
• · Registration Statement Number: 333-296502.
• · CVGI qualifies as a non-accelerated filer (not a large accelerated filer or accelerated filer).
• · Principal executive offices located at 7800 Walton Parkway, New Albany, Ohio 43054.

05-06-2026

Cibus, Inc. held its 2026 Annual Meeting on June 2, 2026, with 69.52% of outstanding shares present, constituting a quorum. All nine director nominees were elected, advisory say-on-pay compensation was approved, and the appointment of BDO USA, P.C. as auditor for 2026 was ratified. However, the high broker non-vote count of 30,383,329 on director elections and the compensation vote indicates significant institutional non-participation or abstention on key governance matters.

• · All nine director nominees received substantial 'for' votes ranging from 22,401,892 to 22,643,935, with minimal 'against' votes (12,213 to 211,345).
• · Advisory say-on-pay compensation was approved with 22,117,686 'for', 167,944 'against', and 403,113 abstentions.
• · Ratification of BDO USA, P.C. as auditor passed overwhelmingly with 53,014,318 'for' and only 36,870 'against' and 20,884 abstentions, with no broker non-votes.
• · The broker non-vote count of 30,383,329 represents approximately 39.8% of total outstanding shares, indicating a large portion of shares held by brokers that did not vote on director elections or compensation.

05-06-2026

Principal Exchange-Traded Funds filed definitive additional proxy materials (DEFA14A) reminding shareholders of the Principal Capital Appreciation Select ETF special meeting scheduled for June 25, 2026. The Board recommends voting FOR the proposal, and the filing notes strong support from fellow shareholders. No financial figures or period-over-period comparisons are included in this solicitation letter.

• · Special Meeting of Shareholders scheduled for June 25, 2026.
• · Shareholders can vote by phone at 1-888-569-8137 (weekdays 10 a.m. to 11 p.m. Eastern) or by internet via the address on the proxy card.
• · Proxy solicitor Sodali Fund Solutions (SFS) is available to assist with voting.
• · The filing is a reminder letter sent less than two weeks before the meeting.

05-06-2026

On June 1, 2026, Invesco Commercial Real Estate Finance Trust, Inc. sold shares of common stock across three classes in unregistered transactions exempt under Section 4(a)(2) of the Securities Act. The sales raised aggregate consideration of approximately $30.1 million, with the largest issuance being Class S-1 common stock (688,777 shares at $24.9801 per share). The transaction price per share was based on the net asset value per share as of April 30, 2026.

• · The transaction price per share for each class was equal to the net asset value per share as of April 30, 2026.
• · Class S-1 shares had upfront selling commissions of $99,159; Class S shares had $1,160; Class I shares had none.
• · The sales were exempt from registration under Section 4(a)(2) of the Securities Act of 1933 as they did not involve a public offering.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

05-06-2026

Matthews International Funds filed a DEFA14A (definitive additional materials) on June 5, 2026, urging shareholders to vote 'FOR' proposals recommended by the Board of Trustees. The filing indicates that shareholders who have already voted have overwhelmingly supported the proposal. No specific financial figures or period comparisons are provided.

• · Filing type: DEFA14A (Definitive Additional Materials)
• · Filing date: June 05, 2026
• · Board of Trustees unanimously recommends voting 'FOR' the proposals
• · Shareholders who have already voted have overwhelmingly supported the proposal
• · Contact number for voting assistance: 1-877-536-1560

05-06-2026

Absci Corporation held its Annual Meeting on June 4, 2026, where stockholders elected Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj as Class II directors and ratified Ernst & Young LLP as independent auditor for fiscal 2026. All proposals were approved, with director elections receiving strong support (over 88% of votes cast for each nominee) and auditor ratification passing overwhelmingly (over 98% of votes cast in favor).

• · The record date for the Annual Meeting was April 7, 2026, with 155,447,428 shares outstanding and entitled to vote.
• · Broker non-votes totaled 29,904,399 for both director nominees.
• · No other matters were submitted to or voted on by stockholders at the meeting.
• · The definitive proxy statement was filed on April 22, 2026.

05-06-2026

Sight Sciences, Inc. held its 2026 annual meeting on June 4, 2026, with 76.2% of outstanding shares represented. Shareholders elected Gerhard Burbach and Staffan Encrantz as Class II directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026. No other matters were voted on.

• · Record date for the annual meeting was April 8, 2026.
• · Broker non-votes totaled 13,617,493 for both director elections.
• · Ratification of Deloitte & Touche LLP received 41,059,471 votes for, 7,892 against, and 388,895 abstentions, with no broker non-votes.
• · No other matters were presented for stockholder action.

05-06-2026

Artelo Biosciences, Inc. has filed definitive additional proxy materials (DEFA14A) with the SEC. This filing provides supplemental information related to the company's proxy solicitation, likely in connection with its annual meeting. No specific financial results or other material metrics are indicated in this filing.